260
Participants
Start Date
October 31, 2007
Primary Completion Date
October 31, 2008
Study Completion Date
November 30, 2008
AEGR-733
3 capsules each evening for each 4-week period
placebo
3 capsules each evening for each 4-week period
AEGR-733
3 capsules each evening for each 4-week period
AEGR-733
3 capsules each evening for each 4-week period
AEGR-733
3 capsules each evening for each 4-week period
AEGR-733 and atorvastatin
3 capsules each evening for each 4-week period
AEGR-733 and fenofibrate
3 capsules each evening for each 4-week period
AEGR-733 and ezetimibe
3 capsules each evening for each 4-week period
University of Pennsylvania, Philadelphia
MedStar Research Institute, Washington D.C.
Health Trends Research, Baltimore
Johns Hopkins, Baltimore
LMARC, Louisville
Sterling Research Group, Cincinnati
University of Iowa, Iowa City
Radiant Research, Chicago
Washington Univ. School of Medicine, St Louis
Baylor College of Medicine, Houston
Clinical Trial Network, Houston
dgd Research, San Antonio
Scripps Clinic, San Diego
Radiant Research, Santa Rosa
Maine Research Associates, Auburn
Lead Sponsor
Aegerion Pharmaceuticals, Inc.
INDUSTRY